News

The latest move follows a collaboration and license agreement signed by the companies in November last year. Sold in the US under the brand name Nurtec ODT, rimegepant

An investigational antibody-drug conjugate (ADC), Teliso-V targets c-Met receptor tyrosine kinase that is overexpressed in tumours that include NSCLC. It is indicated to treat nonsquamous NSCLC patients with

The agreement also includes the lead candidate, OV350, which showed promising in-vitro and in-vivo proof of concept in resistant forms of epilepsy. The early-stage compound directly targets and

The production capacity of ritonavir oral tablets has been expanded to 100 million tablets per year and can also be increased further in future based on the market

AstraZeneca and Ionis Pharmaceuticals have closed a previously announced commercialisation agreement to develop and market experimental therapy, eplontersen, previously called IONIS-TTR-LRX. The deal was announced earlier this month.

The move comes after the Drugs Controller General of India (DCGI) granted emergency use authorization (EUA) for the vaccine, dubbed ‘The World’s COVID-19 Vaccine’. Corbevax technology was engineered

Keytruda is Merck’s an anti-programmed death receptor-1 (PD-1) therapy that hinders the interaction between PD-1 and its ligands, PD-L1 and PD-L2. It increases the ability of the body’s

The acquisition of 3DBT for the consideration amount is to be satisfied by the issuance to the sellers of a total of 33,900,003 consideration shares at 7.37 pence

A fully human biologic, Cosentyx is developed to directly target interleukin-17A (IL-17A), a cytokine. IL-17A is involved in the inflammation of plaque psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis